Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
21 minute read
  • Earnings

Earnings Scheduled For November 8, 2022

By Benzinga Insights
November 8, 5:32 AM
Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.

ABCL

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Morgan Stanley Maintains Overweight on Bioventus, Lowers Price Target to $11

By Benzinga Newsdesk
October 11, 9:54 AM
Morgan Stanley analyst Drew Ranieri maintains Bioventus (NASDAQ:BVS) with a Overweight and lowers the price target from $12 to $11.

BVS

Read More
17 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook

Earnings Scheduled For August 11, 2022

By Benzinga Insights
August 11, 5:09 AM
  Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.

AACG

Read More
5 minute read
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Pre-Market Outlook
  • Small Cap
  • Trading Ideas

Twitter Shares Surge Around 8%, Here’s 66 Biggest Movers From Yesterday

By Lisa Levin
July 14, 5:58 AM
Gainers Qurate Retail, Inc. (NASDAQ: QRTEB) shares climbed 71.1% to close at $5.20. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th.

ABEV

Read More
12 minute read
  • Intraday Update
  • Markets
  • Movers
  • News
  • Options
  • Trading Ideas

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights
July 1, 2:47 PM
  On Friday, 319 stocks hit new 52-week lows.

ADI

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Morgan Stanley Maintains Overweight on Bioventus, Lowers Price Target to $11

By Benzinga Newsdesk
May 12, 10:07 AM
Morgan Stanley maintains Bioventus (NASDAQ:BVS) with a Overweight and lowers the price target from $18 to $11.

BVS

Read More
20 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook

Earnings Scheduled For May 10, 2022

By Benzinga Insights
May 10, 5:18 AM
  Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.

ABCL

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Craig-Hallum Initiates Coverage On Bioventus with Buy Rating, Announces Price Target of $30

By Benzinga Newsdesk
March 15, 7:50 AM
Craig-Hallum initiates coverage on Bioventus (NASDAQ:BVS) with a Buy rating and announces Price Target of $30.

BVS

Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • Health Care
  • News
  • Small Cap

Bioventus Posts Q4 Profit Ahead Of Consensus, Forecasts FY22 Sales Jump Of ~30%

By Vandana Singh
March 10, 12:41 PM
Bioventus Inc's (NASDAQ: BVS) 

BVS

Read More
1 minute read
  • Earnings
  • News

Bioventus Q4 Sales $130.40M Beat $130.29M Estimate

By Bill Haddad
March 10, 8:13 AM
Bioventus (NASDAQ:BVS) reported quarterly sales of $130.40 million which beat the analyst consensus estimate of $130.29 million by 0.08 percent. This is a 32.26 percent increase over sales of $98.59 million the same

BVS

Posts navigation

Previous 1 2 3 4 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service